What is Commodore Capital's new investment in Amylyx Pharmaceuticals?

Commodore Capital disclosed acquiring nearly 4.1 million shares of Amylyx Pharmaceuticals, valued at approximately $55 million.

What does Amylyx Pharmaceuticals develop?

Amylyx Pharmaceuticals develops therapeutics for neurodegenerative diseases, focusing on ALS, with AMX0035 as its lead product.

When are Amylyx Pharmaceuticals' key data readouts expected?

Topline results for Phase 3 LUCIDITY are expected in Q3 2026, and early data for AMX0114 will be presented in December.

Home / Business and Economy / Commodore Capital Bets Big on Amylyx Pharmaceuticals

Commodore Capital Bets Big on Amylyx Pharmaceuticals

5 Dec

•

Summary

Commodore Capital disclosed a new position in Amylyx Pharmaceuticals.
The firm acquired nearly 4.1 million shares valued at $55 million.
Amylyx Pharmaceuticals develops therapies for neurodegenerative diseases.

Commodore Capital Bets Big on Amylyx Pharmaceuticals

Commodore Capital LP, based in New York City, has announced a substantial new investment in Amylyx Pharmaceuticals (NASDAQ:AMLX). The firm disclosed its acquisition of nearly 4.1 million shares, a holding valued at approximately $55 million as of November 14. This strategic move represents 2.7% of Commodore Capital's total reportable equity holdings after the third quarter.

Amylyx Pharmaceuticals is a clinical-stage biotechnology company dedicated to creating novel treatments for neurodegenerative conditions, with a primary focus on amyotrophic lateral sclerosis (ALS). Its lead product candidate is AMX0035, designed as a dual inhibitor of UPR-Bax apoptosis. The company's financial health has shown positive trends, with a more than halved quarterly net loss year-over-year and an extended cash runway projected into 2028, bolstered by a recent public offering.